Dr. Richard MacDonald joined Frezent as an advisor in 2021. Dr. MacDonald brings expertise in cancer cell biology and molecular targeting. Formerly, Dr. MacDonald was a Professor at the University of Nebraska Medical Centre and a leading researcher at the Fred & Pamela Buffett Cancer Centre. His long-standing contributions include serving as the Associate Director of the Nebraska Center for Cellular Signaling, where he contributed to the success of its Phase III CoBRE funding. Dr. MacDonald's research was focused extensively on the insulin-like growth factor (IGF) axis and its role in cancer development, particularly through the IGF-II receptor (M6P/IGF2R). His pioneering studies revealed the mechanisms of receptor dimerization and the function of multivalent ligands in tumorigenesis. His laboratory had over two decades of experience in developing and testing therapeutic compounds that target IGF-II-dependent cancers, including pancreatic cancer.